Chromogranin A is a T cell antigen in human type 1 diabetes

Abstract

Chromogranin A (ChgA) is a beta cell secretory granule protein and a peptide of ChgA, WE14, was recently identified as a ligand for diabetogenic CD4 T cell clones derived from the NOD mouse. In this study we compared responses of human CD4 T cells from recent onset type 1 diabetic (T1D) and control subjects to WE14 and to an enzymatically modified version of this peptide. T cell responders to antigens were detected in PBMCs from study subjects by an indirect CD4 ELISPOT assay for IFN-γ. T1D patients (n = 27) were recent onset patients within one year of diagnosis, typed for HLA-DQ8. Controls (n = 31) were either 1st degree relatives with no antibodies or from the HLA-matched general population cohort of DAISY/TEDDY. A second cohort of patients (n = 11) and control subjects (n = 11) was tested at lower peptide concentrations. We found that WE14 is recognized by T cells from diabetic subjects vs. controls in a dose dependent manner. Treatment of WE14 with transglutaminase increased reactivity to the peptide in some patients. This work suggests that ChgA is an important target antigen in human T1D subjects and that post-translational modification may play a role in its reactivity and relationship to disease.

Keywords: Autoantigen; Autoreactive CD4 T cells; Chromogranin A; Human; Post-translational modification; Type 1 diabetes.

FIG 1

Dose titration responses of cohort 2 subjects to TGase-treated and untreated WE14. PBMCs from T1D patients and controls were incubated with various concentrations of WE14 and TGase-treated WE14. IFN-γ producing cells were detected by indirect ELISPOT analysis and SI values were calculated as described in the Methods section.